Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications

Eight EU marketing authorization applications are up for an opinion this week from the CHMP, the European Medicines Agency committee that recommends whether or not products should be approved.  

Fingers crossed
Companies will be keeping their fingers crossed for a positive CHMP opinion this week

Clovis Oncology is hoping to be proved right in its assumption that the positive feedback the European Medicines Agency recently conferred on its investigational ovarian cancer drug Rubraca (rucaparib) will this week translate into a formal recommendation for EU market approval.

Rubraca, which has orphan drug status, is one of eight products that the EMA’s human medicines committee, the CHMP, is...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet